Fingerprint
Dive into the research topics of 'Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes
Pediatric Eye Disease Investigator Group
Research output: Contribution to journal › Article › peer-review